Small Molecules

Breakthrough Parkinson's Research with LRRK2-IN-1: A Potent and Selective Inhibitor of LRRK2 Kinase Activity

Leucine-Rich Repeat Kinase 2 (LRRK2) is a leucine-rich repeat kinase family member. Mutations in the LRRK2 gene (i.e., G2019S) have been linked with late-onset autosomal dominant Parkinson's disease (PD). Biosensis is proud to offer LRRK2-IN-1, a highly potent and selective inhibitor of LRRK2. LRRK2-IN-1 dynamically blocks wild-type and G2019S mutant LRRK2 kinase activity with exceptional efficacy, displaying IC50 values of 13 nM and 6 nM, respectively. Uncover new horizons in Parkinson's research and the role of LRRK2 in the disease's efficacy with LRRK2-IN-1, a game-changing solution at your fingertips.